

Contents

Chapter 1: Introduction, aims and outline	page 9
Chapter 2: Role of BRI2 in dementia <i>J Alzheimers Dis. 2014;40(3):481-94.</i>	page 27
Chapter 3: BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease. <i>Neurobiol Aging. 2014 Jul;35(7):1596-604.</i>	page 53
Chapter 4: Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of Ab by insulin degrading enzyme (IDE) in Alzheimer's disease. <i>Neurosci Lett. 2015; 589:47-51</i>	page 81
Chapter 5: BRI2 ectodomain affects A β_{42} fibrillation and tau truncation in human neuroblastoma cells. <i>Cell Mol Life Sci. 2015;72(8):1599-611</i>	page 93
Chapter 6: SPPL2b is drastically increased in early stages of Alzheimer's disease and associated with tau pathology. <i>Under review</i>	page 119
Chapter 7: Recommendations to standardize Pre-analytical confounding factors in Alzheimer's and Parkinson's disease CSF biomarkers: an update. <i>Biomark Med. 2012 Aug;6(4):419-30</i>	page 145
Chapter 8: BRI2 correlates with markers reflecting Alzheimer's disease pathology in human cerebrospinal fluid. <i>In preparation</i>	page 167
Chapter 9: Can agrin CSF concentration be used as an early biomarker for Alzheimer's disease? <i>Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring; 2015; 1: 75-80</i>	page 287
Chapter 10: General discussion and perspectives	page 199
Appendix:	
Nederlandse samenvatting	page 222
List of abbreviations	page 225
List of theses Alzheimer Center	page 227
List of publications	page 229
Curriculum Vitae	page 230
Acknowledgements	page 231